XBIO vs. LIXT, SHPH, ENVB, HILS, TFFP, ADIL, PULM, AIMD, PCSA, and CVKD
Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Lixte Biotechnology (LIXT), Shuttle Pharmaceuticals (SHPH), Enveric Biosciences (ENVB), Hillstream BioPharma (HILS), TFF Pharmaceuticals (TFFP), Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Ainos (AIMD), Processa Pharmaceuticals (PCSA), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical preparations" industry.
Lixte Biotechnology (NASDAQ:LIXT) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, dividends, profitability, earnings, media sentiment, valuation and risk.
Xenetic Biosciences received 174 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
In the previous week, Lixte Biotechnology's average media sentiment score of 0.98 beat Xenetic Biosciences' score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media.
Lixte Biotechnology has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500.
5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 15.5% of Lixte Biotechnology shares are owned by insiders. Comparatively, 9.0% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Xenetic Biosciences has higher revenue and earnings than Lixte Biotechnology. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.
Lixte Biotechnology has a net margin of 0.00% compared to Lixte Biotechnology's net margin of -162.84%. Lixte Biotechnology's return on equity of -36.43% beat Xenetic Biosciences' return on equity.
Summary
Xenetic Biosciences beats Lixte Biotechnology on 8 of the 12 factors compared between the two stocks.
Get Xenetic Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenetic Biosciences Competitors List
Related Companies and Tools
